This inventor holds 3 USPTO granted patents and 3 EPO patents. Top assignee: Mei Pharma, Inc.. Active years: 2014-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014-2016
Title: Ken Chi Lik Lee: Innovator in Pharmaceutical Applications
Introduction
Ken Chi Lik Lee is a notable inventor based in Singapore, recognized for his contributions to the field of pharmaceuticals. He holds three patents that focus on innovative compounds with potential therapeutic applications. His work primarily revolves around the development of hydroxamate compounds that serve as inhibitors of histone deacetylase.
Latest Patents
One of Ken Chi Lik Lee's latest patents is centered on imidazo[1,2-a]pyridine derivatives, which are significant for their preparation and pharmaceutical applications. This invention relates to hydroxamate compounds that inhibit histone deacetylase activities. The compounds developed may be useful as medicaments for treating proliferative disorders and other diseases associated with enzymes having histone deacetylase activities.
Career Highlights
Ken Chi Lik Lee is currently associated with Mei Pharma, Inc., where he continues to advance his research and development efforts. His expertise in the pharmaceutical field has led to significant advancements in the treatment of various diseases.
Collaborations
Throughout his career, Ken has collaborated with notable colleagues, including Eric T Sun and Haishan Wang. These collaborations have contributed to the successful development of his innovative compounds.
Conclusion
Ken Chi Lik Lee's work exemplifies the impact of innovation in the pharmaceutical industry. His patents and collaborations highlight his commitment to advancing medical science and improving treatment options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile